SVB Leerink Comments on Marinus Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:MRNS)
SVB Leerink Comments on Marinus Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Investment analysts at SVB Leerink cut their FY2023 earnings estimates for shares of Marinus Pharmaceuticals in a report issued on Monday, January 23rd. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of ($3.25) for the year, down from their prior forecast of ($2.90). SVB Leerink has a "Outperform" rating and a $23.00 price objective on the stock. The consensus estimate for Marinus Pharmaceuticals' current full-year earnings is ($2.88) per share. SVB Leerink also issued estimates for Marinus Pharmaceuticals' FY2024 earnings at ($2.50) EPS, FY2025 earnings at ($1.50) EPS and FY2026 earnings at $1.10 EPS.
Marinus制药公司(纳斯达克代码:MRNS-GET Rating)-SVB Leerink的投资分析师在1月23日(星期一)发布的一份报告中下调了Marinus制药公司2023财年的收益预期。SVB Leerink分析师M.Goodman现在预计,这家生物制药公司今年的每股收益将为3.25美元,低于此前预测的2.90美元。SVB Leerink对该股的评级为“跑赢大盘”,目标价为23.00美元。对Marinus PharmPharmticals目前全年收益的普遍估计为每股2.88美元。SVB Leerink还发布了对Marinus PharmPharmticals 2024财年每股收益(2.50美元)、2025财年每股收益(1.50美元)和2026财年每股收益1.10美元的预期。
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by ($0.60). Marinus Pharmaceuticals had a negative return on equity of 244.60% and a negative net margin of 77.96%. The business had revenue of $2.34 million during the quarter, compared to analysts' expectations of $28.56 million.
马瑞纳斯制药公司(纳斯达克代码:MRNS-GET Rating)最近一次公布财报是在11月7日(星期一)。这家生物制药公司公布本季度每股收益(0.35美元),低于分析师普遍预期的0.25美元(0.60美元)。Marinus制药公司的净资产回报率为负244.60%,净利润率为负77.96%。该业务当季营收为234万美元,高于分析师预期的2,856万美元。
Marinus Pharmaceuticals Trading Up 4.6 %
Marinus制药公司股价上涨4.6%
MRNS opened at $5.96 on Wednesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 8.41 and a quick ratio of 8.40. The company's 50 day simple moving average is $4.47 and its two-hundred day simple moving average is $5.47. Marinus Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $12.37. The firm has a market capitalization of $221.69 million, a price-to-earnings ratio of -12.96 and a beta of 1.10.
周三,MRNS开盘报5.96美元。该公司的债务权益比为0.91,流动比率为8.41,速动比率为8.40。该公司的50日简单移动均线切入位为4.47美元,200日简单移动均线切入位为5.47美元。Marinus PharmPharmticals的一年低点为3.46美元,一年高位为12.37美元。该公司的市值为2.2169亿美元,市盈率为-12.96倍,贝塔系数为1.10。
Institutional Trading of Marinus Pharmaceuticals
Marinus制药公司的制度性交易
Institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $56,000. Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $317,000. Virtu Financial LLC acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $221,000. MetLife Investment Management LLC increased its holdings in Marinus Pharmaceuticals by 63.8% in the 1st quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company's stock valued at $190,000 after purchasing an additional 7,928 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Marinus Pharmaceuticals by 39.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 4,417 shares in the last quarter. Institutional investors and hedge funds own 86.88% of the company's stock.
机构投资者最近增持或减持了该股。合并银行在第一季度收购了Marinus制药公司的新股份,价值约5.6万美元。复兴技术公司在第一季度收购了Marinus制药公司的新股份,价值约31.7万美元。Virtu Financial LLC在第一季度收购了Marinus制药公司的新股份,价值约为221,000美元。大都会人寿投资管理有限责任公司第一季增持Marinus PharmPharmticals股份63.8%。大都会人寿投资管理有限责任公司现在拥有20,363股这家生物制药公司的股票,价值19万美元,在上个季度又购买了7928股。最后,Price T Rowe Associates Inc.MD在第二季度持有的Marinus PharmPharmticals股份增加了39.5%。Price T Rowe Associates Inc.MD现在拥有15,600股这家生物制药公司的股票,价值76,000美元,此前在上个季度又购买了4,417股。机构投资者和对冲基金持有该公司86.88%的股票。
Marinus Pharmaceuticals Company Profile
Marinus制药公司简介
(Get Rating)
(获取评级)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Marinus制药公司是一家制药公司,专注于为患有罕见遗传性癫痫和其他癫痫障碍的患者开发和商业化产品。它提供ZTALMY,一种口服混悬剂,用于治疗与急性和慢性护理中的成人和儿童患者群体以及住院和自我给药环境中的细胞周期蛋白依赖性激酶样缺乏症相关的癫痫发作。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- 免费获取StockNews.com关于Marinus制药的研究报告(MRNS)
- AMD仍是市面上最好的半导体股票之一
- 两大股利大王:强生还是雅培?
- 网络安全类股已经见底了吗?
- 联合太平洋,诺福克南方进入购买区
- 柔顺治疗公司的差距增加了34%:未来还会有更多的好处吗?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Marinus PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Marinus制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。